Literature DB >> 12418049

The genetic pathogenesis of colorectal cancer.

John P Lynch1, Timothy C Hoops.   

Abstract

Research over the past decade has established that the progression from normal colonic epithelium to colon cancer is in every case a step-wise process in which specific pathologic and molecular markers can be identified for study and clinical therapy. Genetic and epigenetic instability appears fundamentally important to this process. We have now determined that this neoplastic progression occurs along a limited set of pathways, in which specific tumor suppressors are inactivated or oncogenes activated in a defined order. Although incomplete, our new understanding of the process of carcinogenesis in the colon has already significantly impacted patient care and will continue to do so for the foreseeable future. Increasingly rapid research developments and technologic advances will transform the way we prevent, diagnose, and treat this common and deadly form of cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12418049     DOI: 10.1016/s0889-8588(02)00029-1

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  12 in total

1.  Serum metabolite profiling of familial adenomatous polyposis using ultra performance liquid chromatography and tandem mass spectrometry.

Authors:  Liyan Sun; Qian Kang; Yuanming Pan; Na Li; Xin Wang; Yuqi He; Haihong Wang; Dongliang Yu; Hui Xie; Lang Yang; Youyong Lu; Peng Jin; Jianqiu Sheng
Journal:  Cancer Biol Ther       Date:  2019-04-14       Impact factor: 4.742

2.  Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.

Authors:  Barbara Mroczko; Maciej Szmitkowski; Urszula Wereszczyńska-Siemiatkowska; Bogna Okulczyk
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

3.  HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.

Authors:  Cassandra A Godman; Rashmi Joshi; Brendan R Tierney; Emily Greenspan; Theodore P Rasmussen; Hsin-Wei Wang; Dong-Guk Shin; Daniel W Rosenberg; Charles Giardina
Journal:  Cancer Biol Ther       Date:  2008-10-07       Impact factor: 4.742

4.  The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex.

Authors:  Rong-Jun Guo; Shinsuke Funakoshi; Hannah H Lee; Jianping Kong; John P Lynch
Journal:  Carcinogenesis       Date:  2009-09-04       Impact factor: 4.944

5.  The diagnostic value of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) measurement in the sera of colorectal cancer patients.

Authors:  Wojciech Jelski; Barbara Mroczko; Maciej Szmitkowski
Journal:  Dig Dis Sci       Date:  2010-01-13       Impact factor: 3.199

6.  Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer.

Authors:  Barbara Mroczko; Maciej Szmitkowski; Urszula Wereszczyńska-Siemiatkowska; Bogna Okulczyk; Bogusław Kedra
Journal:  Int J Colorectal Dis       Date:  2006-03-07       Impact factor: 2.571

7.  Microsatellite instability in colorectal cancer.

Authors:  Matej Horvat; Borut Stabuc
Journal:  Radiol Oncol       Date:  2011-03-15       Impact factor: 2.991

Review 8.  Targeting metastatic colorectal cancer - present and emerging treatment options.

Authors:  Kristen K Ciombor; Jordan Berlin
Journal:  Pharmgenomics Pers Med       Date:  2014-07-08

9.  Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa.

Authors:  N J Belshaw; G O Elliott; R J Foxall; J R Dainty; N Pal; A Coupe; D Garg; D M Bradburn; J C Mathers; I T Johnson
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640

Review 10.  Smad7 and Colorectal Carcinogenesis: A Double-Edged Sword.

Authors:  Edoardo Troncone; Giovanni Monteleone
Journal:  Cancers (Basel)       Date:  2019-05-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.